Avid Bioservices Inc (CDMO)

[biopharm]

Ambit / Peregrine collaboration.... trying to pull a needle from a haystack this has become and darnet, this puzzle will be pieced together sooner or later....

Read the link and at the very end I seen this portion below, not sure what that "..propietary CSF1R inhibitor program" would be or if any collaborators are involved and my guess is there is more to the story. I like how they place that at the very end... Peregrine like. Peregrine Falcon like... just swarming in the high skies above just waiting for that perfect moment for an appearance that is like a knife in the back to some other Big Pharma predators.

Quote:
June 12, 2014
...
..
..

....Quizartinib is also being studied in newly diagnosed patients in combination with chemotherapy as well as maintenance following a hematopoietic stem cell transplantation (HSCT). In addition to quizartinib, Ambit's clinical pipeline includes AC410, an oral JAK2 inhibitor, and CEP-32496, a BRAF inhibitor licensed to Teva Pharmaceutical Industries Ltd. Ambit's preclinical portfolio includes a proprietary CSF1R inhibitor program.

http://www.bizjournals.com/sanfrancisco/prnewswire/press_releases/California/2014/06/12/LA46577

Does anyone know where else Nathanael Gray came up before....lots of Grays lately....though Janne Pasi goes back to moderator for David Gerber back in Sept 2012

https://www.researchgate.net/profile/Nathanael_Gray

......In this collaboration, Dr. Gray's laboratory and the Dana-Farber Medicinal Chemistry Core will be joined by the laboratories of Pasi A. Jänne, M.D., Ph.D., and Kwok-Kin Wong, M.D., Ph.D. of the Thoracic Oncology Program and co-directors of the Belfer Institute for Applied Cancer Science at Dana-Farber and Professors at Harvard Medical School.
...
...
http://www.biospace.com/News/dana-farber-cancer-institute-and-astellas-pharma/352817